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Abstract
A series of new lawsone Mannich bases derived from salicylaldehydes or nitrofurfural
were prepared and tested for their activities against Leishmania major, Toxoplasma
gondii, and Trypanosoma brucei brucei parasites. The hydrochloride salts 5a and 6a of
the Mannich bases 2a and 3a, derived from unsubstituted salicylaldehyde and long‐
chained alkyl amines, were selectively and strongly active against T. gondii cells and
appear to be new promising drug candidates against this parasite. Compound 6a
showed an even higher activity against T. gondii than the known lawsone Mannich
base 1b. Compound 4a, derived from salicylaldehyde and 2‐methylaminopyridine, was
also distinctly active against T. gondii cells. The derivatives 3a (salicyl derivative), 3b
(3,5‐dichloro‐2‐hydroxyphenyl derivative), and 3d (5‐nitrofuranyl derivative) as well
as the hydrochlorides 6a and 6b were also efficacious against T. b. brucei cells with
compounds 3a and 3b being more selective for T. b. brucei over Vero cells when
compared with the known control compound 1b. The derivatives 5a, 5c, 6a, and 6c
proved to be up to five times more active than 1b against L. major promastigotes and
up to four times more efficacious against L. major amastigotes.
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1 | INTRODUCTION
Parasitic diseases still pose an enormous world‐wide medical
challenge.[1] Neglected tropical diseases (NTDs) are particularly
perilous both for locals and travelers in many tropical and subtropical
countries.[2] Due to climate change, further regions of the world are
likely to get affected by these parasitic diseases in the future.[2] New
drugs against NTDs are few and far between because most pharma
companies feel little inclination to develop more efficacious drugs for
diseases mainly affecting people that cannot afford them.[3] Against
this backdrop, it is gratifying that quite a few drug candidates for the
treatment of various NTDs, derived from cheap and renewable
natural products, have emerged lately.[3] Another aspect that needs
to be addressed is the predisposition of immune‐compromised
people to infections such as Toxoplasma gondii.[4]
Lawsone (1a) is a natural 2‐hydroxy‐1,4‐naphthoquinone readily
available from the henna plant (Lawsonia inermis), which is applied for
the management of skin diseases in South Asia as a component of the
local Ayurveda and Unani traditional medicine (Figure 1).[5,6]
Lawsone is a useful starting material for the preparation of various
quinone derivatives with proven bioactivity such as lapachol or
atovaquone.[1,2] The chemical modification of lawsone has led to
compounds with activity against tumor cells and fungi.[7,8] Lawsone
Mannich bases have shown particularly promising activities against
cancer cells and parasites including Trypanosoma brucei brucei and
Entamoeba histolytica.[9–13] We have previously found that longer
alkyl chains attached to the naphthoquinone scaffold as in compound
1b led to enhanced bioactivities (Figure 1).[13] Further, lawsone
derivatives were reported to act against T. gondii, Trypanosoma cruzi,
Leishmania donovani, and Plasmodium falciparum parasites.[14–18] In
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the current study, we prepared new lawsone Mannich bases with
long‐chain appendages and tested their activities against the
cutaneous leishmaniasis causing parasite L. major, against the Nagana
cattle‐disease causing parasite T. b. brucei (both kinetoplastid
parasites), and against toxoplasmosis causing T. gondii parasites (an
apicomplexan parasite).
2 | RESULTS AND DISCUSSION
Compounds 2a–d, 3a–d, and 4a were prepared in moderate yields by
Mannich reactions of lawsone, the respective aryl aldehyde and the
respective amine (Scheme 1).[19] They were obtained as racemic
orange to orange‐red solids. Compounds 2a–c and 3a–c were
converted to the hydrochloride salts 5a–c and 6a–c by reaction
with acetyl chloride in ethyl alcohol (EtOH; Scheme 2).
The new lawsone Mannich bases were tested on three protozoal
parasites including T. gondii against which the related lawsone
derivative atovaquone had already shown reasonable activity.[20] Our
hydrochlorides 5a and 6a proved highly active against T. gondii
tachyzoites, surpassing even the effect of the known positive control
1b (Table 1). Both 5a and 6a also displayed some selectivity for the T.
gondii parasite when compared with nonmalignant Vero cells with
selectivity index (SI) values of 2.38 for 5a and 3.12 for 6a. The new
compounds 4a, 5c, and 6c also exhibited good activities against T.
gondii in the range of that of 1b with some selectivity in the case of 5c
(SI = 1.91) and 6c (SI = 3.38).
The new compounds were also tested for trypanocidal activity
against the bloodstream‐form T. b. brucei parasites using the Alamar
Blue (AB) assay (Table 2). Compounds 3a, 3b, and 3d, carrying a long
hexadecyl chain, reached IC50 values in the low one‐digit micro-
molar concentration range (IC50 = 1.17–1.39 µM) and so performed
better than their dodecyl analogs 2a, 2b, and 2d. It is possible that
3a, 3b, and 3d share similar modes of action with the approved
antileishmanial drug miltefosine, which is a hexadecylphosphocho-
line derivative.[21,22] Interestingly, 3a, 3b, and 3d showed only a
weak activity against T. gondii and Vero cells and the selectivity of
3a and 3b for T. b. brucei was distinctly higher when compared with














































SCHEME 1 Synthesis of compounds 2a–d, 3a–d, and 4a.
Reagents and conditions: (i) Aryl aldehyde, dodecylamine for 2a–d,
hexadecylamine for 3a–d, 2‐aminomethylpyridine for 4a, EtOH, r.t.,
















5a:n = 1, R = H
5b: n = 1, R = Cl
5c: n = 1, R = Br
6a: n = 5, R = H
6b: n = 5, R = Cl
6c:n = 5, R = Br
2a:n = 1, R = H
2b: n = 1, R = Cl
2c:n = 1, R = Br
3a: n = 5, R = H
3b: n = 5, R = Cl
3c: n = 5, R = Br(i)
RR
RR
SCHEME 2 Synthesis of compounds 5a–c and 6a–c. Reagents
and conditions: (i) AcCl, EtOH, 50°C, 1 hr
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Finally, the new compounds were tested against L. major
promastigotes and amastigotes (Table 3). The hydrochlorides 5c,
6a, and 6c were active against the promastigotes with IC50 values
ranging from 5.04 to 6.54 µM, and against the amastigotes with IC50
values between 4.06 and 4.71 µM. The dibromo derivative 6c showed
SI values of 3.19 for promastigotes and 3.97 for amastigotes, each
over Vero cells. The highest activity against the amastigotes was
found for 5a (IC50 = 3.62 µM), which showed a distinctly weaker
activity against the promastigotes. With the exception of the dichloro
derivatives 2b and 3b, all new compounds were more active against
the amastigotes than the promastigotes. The combination of the
lawsone pharmacophore with hydrophobic side‐chains (as in atova-
quone) generates amphiphilic conjugates with potentially enhanced
cell membrane penetration to the effect of an increased cytotoxic
activity. Such a hybrid molecule strategy can indeed lead to
compounds with high activity against L. major.[23] Atovaquone, for
instance, showed a reasonable activity against visceral leishmania-
sis.[24] The observation of a higher activity of most of the new
lawsone Mannich bases against L. major amastigotes compared to
promastigotes supports earlier studies with similar drugs and drug
candidates. The approved antileishmaniasis drug miltefosine proved
toxic to L. major amastigotes without negatively affecting the host
immune system.[25] Ketotifen and cromolyn sodium also performed
better against L. major amastigotes than promastigotes.[26] Another
study described the potent activity of the CM11 peptide against L.
major amastigotes.[27]
3 | CONCLUSIONS
A series of new lawsone Mannich bases derived from (halo‐)
salicylaldehydes and long‐chained alkyl amines (C12 and C16 chains)
were prepared in reasonable yields and were tested against the
pathogenic parasites L. major, T. gondii, and T. b. brucei. New
compounds with inhibitory activities against T. gondii (5a and 6a)
exceeding that of the known 2‐pyridyl lawsone Mannich base 1b
were identified. Compound 6a is a particularly promising new drug
candidate for the treatment of toxoplasmosis, warranting further in‐
depth tests. In addition, we observed a distinctly higher selectivity of
compounds 3a and 3b for T. b. brucei cells when compared to the
known Mannich base 1b. Improved selectivity of 3a and 3b might
lead to less severe side effects in future tests with Trypanosoma
animal models. The most striking data were obtained from tests
against L. major with distinctly improved activities of the new
compounds 5a, 5c, 6a, and 6c when compared with the known
compound 1b. A topical application of these new lawsone Mannich
TABLE 1 Inhibitory concentrations IC50 (µM) of test compounds
1b (positive control), 2a–d, 3a–d, 4a, 5a–c, and 6a–c when applied to
cells of the Vero (African green monkey kidney epithelial) cell line
and effective concentrations of EC50 when applied to cells of
Toxoplasma gondii
Compound EC50 (T. gondii) IC50 (Vero) SI (Vero/T. gondii)
a
1b 4.50 17.4 3.86
2a 126.7 96.2 0.76
2b 15.8 164.1 10.4
2c 10.3 20.3 1.97
2d 40.0 38.3 0.96
3a 45.3 318.3 7.03
3b 51.4 251.5 4.89
3c 9.73 24.2 2.48
3d 64.1 31.7 0.49
4a 4.48 3.73 0.83
5a 3.60 8.56 2.38
5b – <0.1 –
5c 4.71 8.98 1.91
6a 1.56 4.86 3.12
6b – <0.1 –
6c 4.76 16.1 3.38
Note: Values are the means of at least three independent experiments
(standard deviation ± 15%). They were derived from concentration–re-
sponse curves obtained by measuring the percentage of vital cells relative
to untreated controls after 72 hr.
aSelectivity index (SI; IC50/EC50) calculated from the corresponding IC50
values from the Vero cells and the EC50 values against T. gondii.
TABLE 2 Inhibitory concentrations IC50 (µM) of test compounds
1b (positive control), 2a–d, 3a–d, 4a, 5a–c, and 6a–c when applied to
Trypanosoma brucei brucei cellsa


















aValues are the means of at least three independent experiments
(standard deviation ± 15%). They were derived from concentration–re-
sponse curves obtained by measuring the percentage of vital cells relative
to untreated controls after 72 hr.
bSelectivity index (SI) calculated from the corresponding IC50 values from
the Vero cells (Table 1) and the IC50 values against T. b. brucei.
cValue is taken from Ahmed et al.[11]
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bases for the in vivo treatment of cutaneous leishmaniasis caused by




All starting compounds were purchased from Aldrich. The known
compound 1b was prepared according to a literature procedure.[13]
The following instruments were used: melting points (uncorrected),
Gallenkamp; IR spectra, Perkin–Elmer Spectrum One FT‐IR spectro-
photometer with attenuated total reflection (ATR) sampling unit;
nuclear magnetic resonance (NMR) spectra, Bruker Avance 300
spectrometer; chemical shifts are given in parts per million (δ)
downfield from tetramethylsilane as internal standard; mass spectra,
Varian MAT 311 A (EI), UPLC/Orbitrap (ESI); microanalyses, Perki-
n–Elmer 2400 CHN elemental analyzer. All tested compounds are
>95% pure by elemental analysis.
The compound codes together with some biological activity data
are provided as Supporting Information.
4.1.2 | Compound characterization
3‐[(Dodecylamino)(2‐hydroxyphenyl)methyl]‐2‐hydroxy‐1,4‐naphtho-
quinone (2a)
2‐Hydroxy‐1,4‐naphthoquinone (435mg, 2.5mmol) was suspended in
EtOH (15ml), dodecylamine (510mg, 2.75mmol) was added and the
resulting solution was stirred at room temperature for 5 min.
Salicylaldehyde (314 µl, 3.0 mmol) was added and the reaction
mixture was stirred at room temperature for 1 hr. The formed
precipitate was collected, washed with EtOH and dried in vacuum.
Yield: 740mg (1.60mmol, 64%); orange‐red solid of mp 201°C;
νmax (ATR)/cm
−1 3,068, 2,923, 2,852, 2,732, 2,606, 1,679, 1,633,
1,590, 1,515, 1,456, 1,365, 1,274, 1,226, 1,154, 1,100, 1,042, 973,
897, 849, 829, 808, 793, 757, 737, 720, 695, 666, and 627; 1H NMR
(300MHz, CDCl3); δ 0.84 (3H, t, J = 6.7 Hz), 1.1–1.3 (16H, m), 1.3–1.4
(2H, m), 1.7–1.9 (2H, m), 3.0–3.1 (2H, m), 5.87 (1H, s), 6.6–6.8 (2H, m),
6.9–7.0 (1H, m), 7.3–7.4 (2H, m), 7.4–7.5 (1H, m), 7.6–7.7 (1H, m),
7.8–7.9 (1H, m), 9.6–10.0 (1H, br s); 13C NMR (75.5MHz, CDCl3); δ
14.1, 22.7, 26.6, 29.0, 29.3, 29.4, 29.5, 29.6, 31.9, 46.8, 55.4, 59.5,
112.7, 117.1, 118.3, 120.2, 123.1, 125.6, 126.2, 127.2, 129.5, 130.9,
131.5, 132.0, 133.9, 154.8, 164.4, 170.1, 183.1, and 184.5; m/z
(ESI, %) 465.4 (53) [M+], 464.3 (100) [M+], 279.0 (53), 261.0 (98), and
186.2 (98). Anal calcd. C29H37NO4: C, 75.13; H, 8.04; N, 3.02; Found:
C, 75.03; H, 7.98; N, 2.95%.
3‐[(Dodecylamino)(3,5‐dichloro‐2‐hydroxyphenyl)methyl]‐2‐hydroxy‐
1,4‐naphthoquinone (2b)
2‐Hydroxy‐1,4‐naphthoquinone (435mg, 2.5 mmol) and dodecyla-
mine (510mg, 2.75mmol) were dissolved in hot EtOH (10ml) and the
resulting solution was stirred for 5 min. 3,5‐Dichloro‐2‐hydroxyben-
zaldehyde (571mg, 3.0 mmol) was added and the reaction mixture
was slowly cooled down and stirred at room temperature for 30min.
The formed precipitate was collected, washed with EtOH and dried
in vacuum. Yield: 822mg (1.54mmol, 62%); orange solid of mp
TABLE 3 Effective concentrations EC50 (µM) of test compounds 1b (positive control), 2a–d, 3a–d, 4a, 5a, 5c, 6a, and 6c when applied to
promastigotes and amastigotes of Leishmania majora
Compound EC50 (L. major promastigotes) EC50 (L. major amastigotes) SI (Vero/promastigotes)
b SI (Vero/amastigotes)b
1b 25.8 12.3 0.67 1.41
2a 101.8 61.7 0.95 1.56
2b 34.9 58.2 4.70 2.82
2c 13.2 11.6 1.54 1.75
2d 58.0 34.6 0.66 1.11
3a >192.4 32.3 – 9.86
3b 29.9 69.7 8.41 3.61
3c 15.4 7.82 1.57 3.10
3d 60.5 23.0 0.52 1.38
4a 9.83 5.43 0.38 0.69
5a 10.2 3.62 0.84 2.37
5b >200 – – –
5c 6.54 4.71 1.37 1.91
6a 5.57 4.16 0.87 1.17
6b >200 – – –
6c 5.04 4.06 3.19 3.97
aValues are the means of at least three independent experiments (standard deviation ± 15%). They were derived from concentration–response curves
obtained by measuring the percentage of vital cells relative to untreated controls after 72 hr.
bSelectivity index (SI; IC50/EC50) calculated from the corresponding IC50 values from the Vero cells (Table 1) and the EC50 values against L. major.
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188–189°C; 1H NMR (300MHz, CDCl3/dimethyl sulfoxide [DMSO]‐
d6); δ 0.85 (3H, t, J = 6.5 Hz), 1.0–1.2 (18H, m), 2.5–2.7 (2H, m),
2.7–2.9 (2H, m), 5.58 (1H, s), 7.05 (1H, s), 7.27 (1H, s), 7.3–7.5 (2H,
m), and 7.7–7.9 (2H, m); 13C NMR (75.5MHz, CDCl3/DMSO‐d6);
δ 13.7, 22.3, 26.1, 28.6, 28.9, 29.1, 29.2, 31.5, 47.0, 55.0, 110.3, 123.7,
124.0, 125.1, 125.3, 126.1, 127.4, 128.8, 131.0, 131.3, 132.1, 133.6,
149.7, 171.2, 181.9, and 183.5; m/z (%) 357 (22), 346 (100), 289 (64),
255 (52), 105 (98), 77 (42), and 41 (59). Anal calcd. C29H35Cl2NO4: C,
65.41; H, 6.62; N, 2.63; Found: C, 65.31; H, 6.55; N, 2.70%.
3‐[(Dodecylamino)(3,5‐dibromo‐2‐hydroxyphenyl)methyl]‐2‐hydroxy‐
1,4‐naphthoquinone (2c)
2‐Hydroxy‐1,4‐naphthoquinone (435mg, 2.5mmol) and dodecylamine
(510mg, 2.75mmol) were dissolved in hot EtOH (10ml) and the
resulting solution was stirred for 5min. 3,5‐Dibromo‐2‐hydroxybenz-
aldehyde (840mg, 3.0mmol) was added and the reaction mixture was
slowly cooled down and stirred at room temperature for 1 hr. The
formed precipitate was collected, washed with EtOH and dried in
vacuum. Yield: 850mg (1.37mmol, 55%); orange solid of mp
212–214°C; νmax (ATR)/cm
−1 3,177, 3,070, 2,922, 282, 2,551, 1,679,
1,588, 1,497, 1,466, 1,417, 1,372, 1,322, 1,271, 1,230, 1,149, 1,092,
1,052, 988, 917, 881, 864, 840, 821, 795, 746, 733, 712, 691, 665, 629,
and 603; 1H NMR (300MHz, CDCl3); δ 0.8–0.9 (3H, m), 1.1–1.3 (16H,
m), 1.4–1.5 (2H, m), 1.7–1.9 (2H, m), 3.0–3.1 (2H, m), 5.87 (1H, s),
7.3–7.5 (2H, m), 7.5–7.6 (2H, m), 7.7–7.8 (1H, m), and 7.9–8.0 (1H, m);
13C NMR (75.5MHz, CDCl3); δ 14.1, 22.7, 26.4, 26.7, 29.0, 29.3, 29.5,
29.6, 31.9, 47.2, 55.5, 111.9, 125.9, 126.6, 129.1, 130.7, 131.9, 132.6,
133.7, 134.4, 135.0, 138.0, 151.2, 162.9, 170.1, 178.1, and 179.8;
m/z (%) 584 (14), 419 (23), 174 (25), 105 (33), and 44 (100). Anal calcd.




2‐Hydroxy‐1,4‐naphthoquinone (435mg, 2.5 mmol) and dodecyla-
mine (510mg, 2.75 mmol) were dissolved in hot EtOH (10ml) and the
resulting solution was stirred for 5min. 5‐Nitrofuranyl‐2‐carboxal-
dehyde (423mg, 3.0 mmol) was added and the reaction mixture was
slowly cooled down and stirred at room temperature for 30min. The
formed precipitate was collected, washed with EtOH and dried in
vacuum. Yield: 371mg (0.77mmol, 31%); orange‐red solid of mp
168–169°C; νmax (ATR)/cm
−1 2,923, 2,853, 1,675, 1,623, 1,589,
1,527, 1,495, 1,470, 1,370, 1,353, 1,321, 1,158, 1,017, 969, 873,
810, 774, 733, 719, 693, 680, and 663; 1H NMR (300MHz, DMSO‐
d6); δ 0.85 (3H, t, J = 6.5 Hz), 1.1–1.3 (18H, m), 1.5–1.7 (2H, m),
2.8–2.9 (2H, m), 5.73 (1H, s), 6.91 (1H, d, J = 3.8 Hz), 7.6–8.0 (5H, m),
9.1–9.3 (1H, br s); 13C NMR (75.5MHz, DMSO‐d6); δ 13.9, 22.0, 25.2,
25.7, 26.7, 28.3, 28.4, 28.6, 28.7, 28.8, 28.9, 30.0, 31.2, 45.2, 51.4,
60.8, 106.6, 112.8, 114.0, 114.2, 114.8, 115.6, 118.9, 125.3, 125.5,
125.7, 130.9, 132.1, 132.9, 133.8, 133.9, 134.6, 149.5, 152.5, 160.8,
164.7, 171.2, 178.2, and 183.9; m/z (%) 291 (4), 262 (15), 209 (9), 195
(100), 154 (30), 108 (15), 79 (30), 55 (34), and 41 (46). Anal calcd.




2‐Hydroxy‐1,4‐naphthoquinone (435mg, 2.5 mmol) was suspended in
EtOH (15ml), dodecylamine (664mg, 2.75mmol) was added and the
resulting solution was stirred at room temperature for 5 min.
Salicylaldehyde (314 µl, 3.0 mmol) was added and the reaction
mixture was stirred at room temperature for 1 hr. The formed
precipitate was collected, washed with EtOH and dried in vacuum.
Yield: 636mg (1.22mmol, 49%); orange‐red solid of mp 208–209°C;
νmax (ATR)/cm
−1 3,069, 2,922, 2,851, 2,738, 1,679, 1,590, 1,516,
1,456, 1,363, 1,274, 1,233, 1,155, 1,099, 1,041, 973, 883, 849, 828,
793, 756, 737, 720, 695, 666, and 626; 1H NMR (300MHz, CDCl3);
δ 0.85 (3H, t, J = 6.7 Hz), 1.0–1.2 (24H, m), 1.3–1.4 (2H, m), 1.8–1.9
(2H, m), 3.0–3.1 (2H, m), 5.86 (1H, s), 6.6–6.8 (2H, m), 6.9–7.0 (1H, m),
7.3–7.4 (2H, m), 7.4–7.5 (1H, m), 7.6–7.7 (1H, m), and 7.8–7.9 (1H, m);
13C NMR (75.5MHz, CDCl3); δ 14.0, 22.7, 26.5, 29.0, 29.3, 29.5, 29.6,
29.7, 31.9, 46.7, 55.4, 112.8, 118.5, 120.3, 123.2, 125.6, 126.2, 127.2,
129.5, 130.8, 131.5, 133.9, 134.0, 154.8, 170.1, 183.0, and 184.5; m/z
(ESI, %) 521.5 (35) [M+], 520.4 (93) [M+], 261.0 (58), and 242.3 (100).




2‐Hydroxy‐1,4‐naphthoquinone (435mg, 2.5 mmol) and hexadecyla-
mine (664mg, 2.75mmol) were dissolved in hot EtOH (10ml) and the
resulting solution was stirred for 5min. 3,5‐Dichloro‐2‐hydroxybenz-
aldehyde (571mg, 3.0 mmol) was added and the reaction mixture
was slowly cooled down and stirred at room temperature for 1 hr.
The formed precipitate was collected, washed with EtOH and dried in
vacuum. Yield: 812mg (1.38mmol, 55%); orange‐red solid of mp
181–182°C; νmax (ATR)/cm
−1 2,922, 2,852, 1,677, 1,590, 1,506,
1,467, 1,368, 1,274, 1,234, 1,168, 1,095, 1,055, 992, 864, 826, 735,
719, 699, 666, and 611; 1H NMR (300MHz, CDCl3); δ 0.85 (3H, t,
J = 6.5 Hz), 1.0–1.3 (26H, m), 1.7–1.9 (2H, m), 3.0–3.2 (2H, m), 5.91
(1H, s), 7.0–7.1 (1H, m), 7.3–7.8 (4H, m), 7.9–8.0 (1H, m), and
9.7–10.0 (1H, br s); 13C NMR (75.5MHz, CDCl3); δ 14.6, 22.7, 26.4,
26.6, 28.9, 29.3, 29.5, 29.7, 31.9, 47.1, 55.3, 111.2, 124.7, 125.9,
126.5, 128.8, 129.5, 130.7, 131.8, 132.5, 133.7, 134.4, 149.7, 163.0,
170.1, 183.2, and 184.4; m/z (%) 413 (72), 244 (76), 174 (93), 105
(100), 55 (51), and 43 (73). Anal calcd. C33H43Cl2NO4: C, 67.34; H,
7.36; N, 2.38; Found: C, 67.22; H, 7.28; N, 2.30%.
3‐[(Hexadecylamino)(3,5‐dibromo‐2‐hydroxyphenyl)methyl]‐2‐hydro-
xy‐1,4‐naphthoquinone (3c)
2‐Hydroxy‐1,4‐naphthoquinone (435mg, 2.5 mmol) and hexadecyla-
mine (664mg, 2.75mmol) were dissolved in hot EtOH (10ml) and the
resulting solution was stirred for 5 min. 3,5‐Dibromo‐2‐hydroxybenz-
aldehyde (840mg, 3.0 mmol) was added and the reaction mixture
was slowly cooled down and stirred at room temperature for 1 hr.
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The formed precipitate was collected, washed with EtOH and dried in
vacuum. Yield: 837mg (1.24mmol, 50%); orange solid of mp
202–203°C; νmax (ATR)/cm
−1 3,039, 2,921, 2,852, 2,551, 1,676,
1,589, 1,506, 1,466, 1,435, 1,417, 1,367, 1,303, 1,272, 1,234, 1,149,
1,093, 1,054, 991, 916, 864, 837, 823, 796, 748, 735, 713, 690, 666,
656, 629, and 600; 1H NMR (300MHz, CDCl3); δ 0.8–0.9 (3H, m),
1.1–1.5 (24H, m), 1.7–1.9 (2H, m), 3.0–3.2 (2H, m), 5.85 (1H, s), and
7.4–8.1 (6H, m); 13C NMR (75.5MHz, DMSO‐d6); δ 13.9, 22.0, 25.3,
26.0, 28.3, 28.4, 28.6, 28.8, 28.9, 31.2, 46.2, 53.7, 103.7, 110.2, 110.6,
110.8, 112.5, 117.1, 125.3, 125.7, 125.9, 128.5, 129.0, 131.0, 131.2,
131.6, 133.1, 133.6, 133.9, 134.0, 138.0, 151.5, 165.2, 171.4, 180.2,
and 183.2; m/z (%) 639 (26), 503 (27), 436 (87), 420 (33), 334 (47),
105 (100), 55 (43), and 44 (68). Anal calcd. C33H43Br2NO4: C, 58.50;
H, 6.40; N, 2.07; Found: C, 58.43; H, 6.37; N, 2.13%.
3‐[(Hexadecylamino)(5‐nitrofuran‐2‐yl)methyl]‐2‐hydroxy‐1,4‐
naphthoquinone (3d)
2‐Hydroxy‐1,4‐naphthoquinone (435mg, 2.5 mmol), and hexadecyla-
mine (664mg, 2.75 mmol) were dissolved in hot EtOH (10ml) and the
resulting solution was stirred for 5min. 5‐Nitrofuranyl‐2‐carboxal-
dehyde (423mg, 3.0 mmol) was added and the reaction mixture was
slowly cooled down and stirred at room temperature for 30min. The
formed precipitate was collected, washed with EtOH and dried in
vacuum. Yield: 400mg (0.74mmol, 30%); orange‐red solid of mp
152–154°C; νmax (ATR)/cm
−1 2,921, 2,852, 1,676, 1,621, 1,589,
1,528, 1,496, 1,469, 1,371, 1,353, 1,320, 1,273, 1,241, 1,158, 1,017,
968, 873, 828, 810, 775, 734, 720, 693, 680, and 662; 1H NMR
(300MHz, DMSO‐d6); δ 0.85 (3H, t, J = 6.5 Hz), 1.1–1.3 (26H, m),
1.5–1.7 (2H, m), 2.8–2.9 (2H, m), 5.73 (1H, s), 6.91 (1H, d, J = 4.4 Hz),
7.6–8.0 (5H, m), and 9.2–9.4 (1H, br s); 13C NMR (75.5MHz, DMSO‐
d6); δ 13.9, 22.1, 25.2, 25.8, 28.4, 28.5, 28.7, 28.9, 31.3, 45.2, 51.4,
106.6, 112.8, 114.2, 115.6, 125.2, 125.3, 125.6, 125.8, 130.9, 131.6,
132.1, 133.8, 133.9, 134.6, 155.0, 171.2, 178.2, and 183.9; m/z (%)
347 (8), 318 (23), 195 (100), and 154 (17). Anal calcd. C31H42N2O6:
C, 69.12; H, 7.86; N, 5.20; Found: C, 68.99; H, 7.79; N, 5.14%.
3‐[Pyridine‐2‐methylamino)(2‐hydroxyphenyl)methyl]‐2‐hydroxy‐
1,4‐naphthoquinone (4a)
2‐Hydroxy‐1,4‐naphthoquinone (435mg, 2.5mmol) was suspended in
EtOH (10ml), 2‐aminomethylpyridine (281 µl, 2.75 mmol) was added
and the resulting solution was stirred at room temperature for 5min.
Salicylaldehyde (314 µl, 3.0 mmol) was added and the reaction
mixture was stirred at room temperature for 2 hr. The formed
precipitate was collected, washed with EtOH and dried in vacuum.
Yield: 412mg (1.07mmol, 43%); orange solid of mp 187–189°C;
νmax (ATR)/cm
−1 3,057, 2,769, 2,611, 1,672, 1,608, 1,590, 1,537,
1,475, 1,455, 1,356, 1,335, 1,273, 1,253, 1,239, 1,220, 1,190, 1,154,
1,097, 1,035, 997, 959, 937, 904, 870, 826, 797, 749, 735, 719, 697,
679, 662, 636, and 612; 1H NMR (300MHz, DMSO‐d6); δ 4.1–4.3
(2H, m), 5.84 (1H, s), 6.7–6.9 (2H, m), 7.1–7.2 (1H, m), 7.3–7.5 (3H, m),
7.6–7.7 (1H, m), 7.7–8.0 (5H, m), 8.5–8.6 (1H, m), and 9.6–10.0 (2H,
br s); 13C NMR (75.5MHz, DMSO‐d6); δ 42.7, 49.7, 54.3, 63.8, 92.4,
110.2, 115.9, 116.5, 117.0, 118.6, 119.0, 122.5, 122.7, 123.1, 123.3,
125.0, 125.8, 126.9, 127.5, 128.6, 129.3, 130.2, 130.9, 131.6, 132.9,
133.1, 133.7, 134.8, 137.0, 137.2, 148.9, 155.5, 167.4, 171.4, 179.3,
and 184.0; m/z (ESI, %) 387.2 (95) [M+], 372.2 (38), 264.1 (100), and
109.1 (98). Anal calcd. C23H18N2O4: C, 71.49; H, 4.70; N, 7.25;
Found: C, 71.20; H, 4.63; N, 7.08%.
3‐[(Dodecylamino)(2‐hydroxyphenyl)methyl]‐2‐hydroxy‐1,4‐naphtho-
quinone × HCl (5a)
2a (231mg, 0.5 mmol) was dissolved in ethanol (20ml) upon heating
and treated with acetyl chloride (53 µl, 0.75mmol). The resulting
yellow solution was stirred at 50°C for 1 hr. The solvent was
evaporated and the yellow solid residue was dried in vacuum. Yield:
250mg (0.5 mmol, 100%); yellow‐orange solid of mp 144–146°C;
νmax (ATR)/cm
−1 3,071, 2,922, 2,853, 2,729, 1,683, 1,640, 1,593,
1,506, 1,457, 1,362, 1,268, 1,218, 1,157, 1,093, 1,046, 953, 881, 796,
755, 722, 696, and 658; 1H NMR (300MHz, CDCl3); δ 0.84 (3H, t,
J = 6.7 Hz), 1.0–1.2 (18H, m), 1.7–1.9 (2H, m), 2.9–3.1 (2H, m), 6.00
(1H, s), 6.7–6.8 (1H, m), 7.0–7.1 (1H, m), 7.2–7.4 (2H, m), 7.5–7.6 (1H,
m), 7.7–7.8 (1H, m), 7.8–7.9 (1H, m), 8.0–8.1 (1H, m), 8.6–8.7 (1H, br
s), and 10.1–10.3 (1H, br s); 13C NMR (75.5MHz, CDCl3); δ 14.1,
22.7, 26.3, 26.6, 29.0, 29.3, 29.5, 29.6, 31.9, 46.8, 54.6, 116.2, 117.7,
118.7, 120.5, 126.7, 127.0, 129.5, 130.9, 132.2, 133.5, 135.3, 155.3,
155.7, 180.2, and 185.1; m/z (%) 426 (57), 402 (20), 286 (19), 261
(100), and 247 (42). Anal calcd. C29H38ClNO4: C, 69.65; H, 7.66; N,
2.80; Found: C, 69.60; H, 7.59; N, 2.75%.
3‐[(Dodecylamino)(3,5‐dichloro‐2‐hydroxyphenyl)methyl]‐2‐hydroxy‐
1,4‐naphthoquinone × HCl (5b)
2b (266mg, 0.5 mmol) was dissolved in ethanol (25ml) upon heating
and treated with acetyl chloride (53 µl, 0.75mmol). The resulting
yellow solution was stirred at 50°C for 1 hr. The solvent was
evaporated and the yellow solid residue was dried in vacuum. Yield:
284mg (0.5 mmol, 100%); yellow‐orange solid of mp 151–153°C;
νmax (ATR)/cm
−1 2,921, 2,852, 1,679, 1,644, 1,590, 1,520, 1,466,
1,414, 1,365, 1,305, 1,275, 1,218, 1,160, 1,095, 1,046, 861, 794, 754,
725, 700, 665, 652, and 635; 1H NMR (300MHz, CDCl3); δ 0.7–0.8
(3H, m), 1.1–1.3 (18H, m), 1.8–1.9 (2H, m), 3.0–3.1 (2H, m), 6.05 (1H,
s), 7.19 (1H, s), 7.44 (1H, s), 7.5–7.7 (2H, m), 7.8–7.9 (1H, m), and
8.0–8.1 (1H, m); 13C NMR (75.5MHz, CDCl3); δ 14.1, 22.6, 26.1, 26.6,
29.0, 29.3, 29.4, 29.5, 29.6, 31.9, 47.5, 53.9, 114.7, 124.2, 124.4,
126.0, 126.7, 126.9, 128.0, 130.4, 132.3, 133.4, 135.1, 149.4, 180.5,
and 184.6; m/z (%) 495 (88), 355 (34), 330 (100), 239 (21), 174 (43),
and 105 (43). Anal calcd. C29H36Cl3NO4: C, 61.22; H, 6.38; N, 2.46;
Found: C, 61.13; H, 6.33; N, 2.42%.
3‐[(Dodecylamino)(3,5‐dibromo‐2‐hydroxyphenyl)methyl]‐2‐hydroxy‐
1,4‐naphthoquinone × HCl (5c)
2c (310mg, 0.5 mmol) was dissolved in ethanol (25 ml) upon heating
and treated with acetyl chloride (53 µl, 0.75mmol). The resulting
yellow solution was stirred at 50°C for 1 hr. The solvent was
evaporated and the yellow solid residue was dried in vacuum. Yield:
320mg (0.49mmol, 98%); yellow‐orange solid of mp 115–117°C;
νmax (ATR)/cm
−1 2,922, 2,852, 1,679, 1,645, 1,590, 1,516, 1,459,
6 of 9 | AL NASR ET AL.
1,364, 1,275, 1,218, 1,143, 1,093, 1,046, 865, 794, 723, 689, 657,
625, 610, and 601; 1H NMR (300MHz, CDCl3); δ 0.7–0.9 (3H, m),
1.1–1.3 (18H, m), 1.8–1.9 (2H, m), 3.0–3.1 (2H, m), 6.03 (1H, s), 7.47
(1H, s), 7.5–7.6 (2H, m), 7.6–7.7 (1H, m), 7.8–7.9 (1H, m), and 8.0–8.1
(1H, m); 13C NMR (75.5MHz, DMSO‐d6); δ 13.9, 22.0, 25.2, 25.8,
28.4, 28.5, 28.6, 28.7, 28.8, 28.9, 31.2, 46.2, 52.7, 110.7, 111.0, 111.9,
112.7, 125.4, 125.8, 128.0, 129.9, 130.9, 131.9, 132.3, 133.0, 133.2,
134.0, 134.3, 134.4, 138.2, 140.5, 151.3, 167.1, 181.4, 182.1, and
192.9; m/z (%) 600 (12), 584 (57), 517 (59), 444 (18), 419 (100), 333
(26), 174 (67), 105 (48), 43 (40), and 36 (11). Anal calcd.
C29H36Br2ClNO4: C, 52.95; H, 5.52; N, 2.13; Found: C, 53.01;
H, 5.60; N, 2.09%.
3‐[(Hexadecylamino)(2‐hydroxyphenyl)methyl]‐2‐hydroxy‐1,4‐
naphthoquinone × HCl (6a)
3a (260mg, 0.5mmol) was dissolved in ethanol (20 ml) upon heating
and treated with acetyl chloride (53 µl, 0.75 mmol). The resulting
yellow solution was stirred at 50°C for 1 hr. The solvent was
evaporated and the yellow solid residue was dried in vacuum. Yield:
278mg (0.5 mmol, 100%); yellow‐orange solid of mp 142–144°C;
νmax (ATR)/cm
−1 3,070, 2,922, 2,852, 1,678, 1,646, 1,594, 1,507,
1,457, 1,355, 1,274, 1,218, 1,158, 1,097, 1,044, 1,028, 947, 862, 837,
794, 753, 724, 696, and 655; 1H NMR (300MHz, CDCl3); δ 0.85 (3H,
t, J = 6.7 Hz), 1.0–1.3 (26H, m), 1.6–1.8 (2H, m), 2.9–3.1 (2H, m), 6.00
(1H, s), 6.7–6.8 (1H, m), 7.0–7.1 (1H, m), 7.2–7.4 (2H, m), 7.5–7.6 (1H,
m), 7.7–7.8 (1H, m), 7.8–7.9 (1H, m), 8.0–8.1 (1H, m), 8.6–8.7 (1H, br
s), and 10.2–10.3 (1H, br s); 13C NMR (75.5MHz, CDCl3); δ 14.1,
22.7, 26.3, 26.7, 29.0, 29.3, 29.5, 29.6, 29.7, 31.9, 46.8, 54.7, 116.2,
117.7, 118.6, 120.5, 124.8, 126.5, 126.7, 127.0, 129.4, 129.6, 130.9,
132.2, 133.5, 135.3, 155.3, 180.2, and 185.1; m/z (%) 500 (25), 482
(100), 287 (18), 262 (97), 233 (26), and 206 (29). Anal calcd.
C33H46ClNO4: C, 71.26; H, 8.34; N, 2.52; Found: C, 71.16; H, 8.28;
N, 2.48%.
3‐[(Hexadecylamino)(3,5‐dichloro‐2‐hydroxyphenyl)methyl]‐2‐hydro-
xy‐1,4‐naphthoquinone × HCl (6b)
3b (294mg, 0.5mmol) was dissolved in ethanol (25ml) upon heating
and treated with acetyl chloride (53 µl, 0.75 mmol). The resulting
yellow solution was stirred at 50°C for 1 hr. The solvent was
evaporated and the residue was recrystallized from CH2Cl2/n‐
hexane. Yield: 246mg (0.39mmol, 79%); yellow‐orange solid of mp
171–173°C; νmax (ATR)/cm
−1 2,918, 2,850, 1,683, 1,668, 1,615,
1,592, 1,574, 1,546, 1,519, 1,470, 1,440, 1,379, 1,362, 1,277, 1,245,
1,218, 1,173, 1,142, 1,046, 990, 937, 883, 860, 818, 756, 743, 732,
720, 702, 639, 624, and 611; 1H NMR (300MHz, CDCl3); δ 0.85 (3H,
t, J = 6.7 Hz), 1.1–1.3 (26H, m), 1.7–1.9 (2H, m), 2.9–3.1 (2H, m), 6.09
(1H, s), 7.20 (1H, s), 7.32 (1H, s), 7.6–7.8 (2H, m), 7.7–7.8 (1H, m),
8.0–8.1 (1H, m), and 8.2–8.3 (1H, m); 13C NMR (75.5MHz, CDCl3);
δ 14.1, 22.7, 26.1, 26.6, 26.7, 27.6, 29.0, 29.4, 29.5, 29.6, 29.7, 31.9,
40.2, 47.4, 53.6, 114.7, 117.7, 124.1, 124.3, 126.0, 126.7, 126.9,
127.9, 129.8, 130.4, 131.1, 132.3, 133.3, 133.4, 135.1, 135.3, 136.5,
149.4, 180.7, and 184.7; m/z (%) 500 (25), 482 (100), 287 (18), 262
(97), 233 (26), and 206 (29). m/z (%) 567 (6), 551 (100), 471 (8), 395
(17), 355 (30), 332 (26), 174 (34), 105 (32), and 43 (17). Anal calcd.
C33H44Cl3NO4: C, 63.41; H, 7.10; N, 2.24; Found: C, 63.33; H, 7.05;
N, 2.19%.
3‐[(Hexadecylamino)(3,5‐dibromo‐2‐hydroxyphenyl)methyl]‐2‐hydro-
xy‐1,4‐naphthoquinone × HCl (6c)
3c (338mg, 0.5 mmol) was dissolved in ethanol (25 ml) upon heating
and treated with acetyl chloride (53 µl, 0.75mmol). The resulting
yellow solution was stirred at 50°C for 1 hr. The solvent was
evaporated and the residue was recrystallized from CH2Cl2/n‐
hexane. Yield: 318mg (0.46mmol, 92%); yellow‐orange solid of mp
120–122°C; νmax (ATR)/cm
−1 3,373, 3,192, 2,922, 2,851, 2,636,
1,685, 1,616, 1,589, 1,574, 1,544, 1,465, 1,440, 1,405, 1,378, 1,360,
1,275, 1,239, 1,219, 1,158, 1,133, 1,096, 1,042, 988, 922, 886, 860,
835, 817, 799, 751, 731, 705, 695, 637, and 624; 1H NMR (300MHz,
CDCl3); δ 0.85 (3H, t, J = 6.7 Hz), 1.1–1.3 (26H, m), 1.8–2.0 (2H, m),
3.0–3.1 (2H, m), 6.01 (1H, s), 7.55 (1H, s), 7.6–7.8 (3H, m), 7.9–8.0
(1H, m), and 8.0–8.1 (1H, m); 13C NMR (75.5MHz, CDCl3); δ 14.1,
22.7, 26.1, 26.6, 29.0, 29.2, 29.4, 29.5, 29.6, 29.7, 31.9, 40.2, 47.5,
53.9, 113.7, 114.7, 115.0, 124.3, 126.5, 126.8, 127.1, 129.7, 131.8,
132.2, 133.1, 133.7, 135.2, 136.1, 142.0, 150.7, 157.1, 180.2, and
184.8; m/z (%) 640 (100), 444 (21), 419 (16), 174 (24), 105 (17), 57
(13), and 43 (19). Anal calcd. C33H44Br2ClNO4: C, 55.51; H, 6.21; N,
1.96; Found: C, 55.46; H, 6.13; N, 1.92%.
4.2 | Biological assays
4.2.1 | Leishmania major cell isolation, culture
conditions, and assays
Promastigotes of L. major were isolated from a Saudi male patient in
February 2016 and maintained at 26°C in Schneider’s Drosophila
medium (Invitrogen) supplemented with 10% heat‐inactivated fetal
bovine serum (FBS; Invitrogen) and antibiotics in a tissue culture
flask with weekly transfers. Promastigotes were cryopreserved in
liquid nitrogen at concentrations of 3 × 106 parasites/ml. The
virulence of L. major parasites was maintained by passing in female
BALB/c mice by injecting hind footpads with 1 × 106 stationary‐phase
promastigotes. After 8 weeks, L. major amastigotes were isolated
from mice. Isolated amastigotes were transformed to promastigote
forms by culturing at 26°C in Schneider’s medium supplemented with
10% FBS and antibiotics. For infection, amastigote‐derived promas-
tigotes with less than five in vitro passages were used. Male and
female BALB/c mice were obtained from Pharmaceutical College,
King Saud University, Kingdom of Saudi Arabia, and maintained in
specific pathogen‐free facilities.
To evaluate the activity of test compounds against L. major
promastigotes, promastigotes from logarithmic‐phase cultured in
phenol red‐free Rosewell Park Memorial Institute (RPMI)‐1640
medium (Invitrogen) with 10% FBS were suspended on 96‐wells
plates to yield 106 cells/ml (200 µl/well) after hemocytometer
counting. Compounds were added to obtain the final concentrations
(200, 40, 8, 1.6, etc. µg/ml). Negative control wells containing
cultures with DMSO (1%) and without compound and positive
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control wells containing cultures with decreasing concentration of
amphotericin B (reference compound, 200, 40, 8, 1.6, etc. µg/ml)
were used. Plates were incubated at 26°C for 24, 48, and 72 hr to
evaluate the antiproliferative effect. The number of viable promas-
tigotes were assessed by the colorimetric method using tetrazolium
dye (3‐[4,5‐dimethylthiazol‐2‐yl]‐2,5‐diphenyltetrazolium bromide,
MTT). It measures the reduction of the MTT component into an
insoluble formazan product. This colored product was solubilized by
adding detergent solution to lyse the cells. The samples were
analyzed by using an enzyme‐linked immunosorbent assay reader at
570 nm. Obtained EC50 values resulted from three independent
experiments.
To evaluate the activity of test compounds against amastigotes in
macrophages, peritoneal macrophages from female BALB/c (6–8
weeks of age) were collected by aspiration, then 5 × 104 cells/well
were seeded on 96‐wells plates in phenol red‐free RPMI‐1640
medium with 10% FBS, for 4 hr at 37°C in 4% CO2 atmosphere to
promote cell adhesion. The medium was discarded and washed with
phosphate‐buffered saline (PBS). Two hundred microliters of solution
containing L. major promastigotes (at the ratio of 10 promastigotes/1
macrophage in phenol red‐free RPMI‐1640 medium with 10% FBS)
was added per well. Plates were incubated for 24 hr at 37°C in
humidified 5% CO2 atmosphere to allow infection and amastigote
differentiation. Then, the infected macrophages were washed three
times with PBS to remove the free promastigotes and overlaid with
fresh phenol red‐free RPMI‐1640 medium containing compounds at
final concentrations (200, 40, 8, 1.6, etc. µg/ml) were added and cells
were incubated at 37°C in humidified 5% CO2 atmosphere for 72 hr.
Negative control containing cultures with DMSO (1%) and without
compounds and positive control wells containing cultures with
decreasing concentration of amphotericin B (reference compound,
200, 40, 8, 1.6, etc. µg/ml) were used. The percentage of infected
macrophages was evaluated microscopically after removing medium,
washing, fixation, and Giemsa staining. Obtained EC50 values
resulted from three independent experiments.
4.2.2 | T. gondii cell line, culture conditions, and
assay
Serial passages of the Vero cell line (ATCC®, CCL81™) were used for
the cultivation of T. gondii tachyzoites of the RH strain (a gift from Dr.
Saeed El‐Ashram, State Key Laboratory for Agrobiotechnology, China
Agricultural University, Beijing, China). Vero cells were cultured by
using complete RPMI‐1640 medium with heat‐inactivated 10% FBS
in a humidified 5% CO2 atmosphere at 37°C. 96‐Well plates (5 × 103
cells/well in 200 µl RPMI‐1640 medium with 10% FBS) were used for
the cultivation of the Vero cells and then incubated at 37°C and 5%
CO2 for 1 day, followed by removal of medium and washing the cells
with PBS. Then, RPMI‐1640 medium with 2% FBS containing
tachyzoites (RH strain) of T. gondii at a ratio of 5:1 (parasite/Vero
cells) was added. After incubation at 37°C and 5% CO2 for 6 hr, the
cells were washed with PBS and then treated as described below.
Control: RPMI‐1640 medium only. Experimental: Medium + com-
pounds (dissolved in DMSO; 50 µg/ml, 25, 12.5, etc.). After incubation
at 37°C and 5% CO2 for 72 hr, the cells were stained with 1%
toluidine blue after washing with PBS and fixation in 10% formalin.
The cells were examined under an inverted photomicroscope to
determine the infection index (number of cells infected from 200
cells tested) of T. gondii. The following equation was used for the
calculation of the observed inhibition (in %):
( ) = ( – )/( ) ×I I IInhibition % 100,Control Experimental Control
where IControl refers to the infection index of untreated cells and
IExperimental refers to the infection index of cells treated with test
compounds.
Then, effects of test compounds on parasite growth were
expressed as EC50 (effective concentration at 50%) values.
4.2.3 | Trypanosoma cell line and culture conditions
T. b. brucei bloodstream‐form cell strain Lister 427 was maintained in
HMI‐9 medium, pH 7.5, supplemented with 10% FBS in a humidified
5% CO2 atmosphere at 37°C.
[28]
4.2.4 | Alamar blue (AB) assay
The AB assay was used to identify viable cells after treatment with
drug candidates.[29–32] This assay is based on the irreversible reaction
of the blue dye resazurin and NADH to pink resofurin in intact cells.
T. b. brucei cells (8,000/well) were seeded on 96‐well microplates,
treated with the test compounds (dissolved in DMSO) and incubated
for 72 hr (5% CO2, 95% humidity, 37°C). Ten microliters of the AB
reagent (500 µM resazurin sodium salt in PBS) was added and
incubated for further 4 hr at 37°C. The fluorescence (extinction at
544 nm, emission at 590 nm) was measured on an Omega Fluostar
(BMG Labtech) fluorescence plate reader.
4.2.5 | In vitro cytotoxicity assay
Tetrazolium salt colorimetric assay (MTT) was carried out for
cytotoxicity evaluation of compounds. Briefly, Vero cells were
cultured in 96‐well plates (5 × 103 cells/well per 200 µl) for 24 hr in
RPMI‐1640 medium with 10% FBS and 5% CO2 at 37°C. The cells
were washed with PBS and treated with test compounds for 72 hr at
varying concentrations (50 µg/ml, 25, 12.5, etc.) in a medium with
10% FBS. As negative control, cells were treated with a medium
containing 10% FBS. The cells were left for incubation with the test
compounds for 72 hr. Thereafter, the supernatant was removed and
100 µl RPMI‐1640 medium containing 10 µl MTT (5mg/ml) was
added and incubated for 4 hr. After that, the supernatant was
removed and 200ml DMSO was added to dissolve the formazan. A
FLUOstar OPTIMA spectrophotometer was used for colorimetric
analysis (λ = 540 nm). Cytotoxic effects were expressed by IC50
values (concentration that caused a 50% reduction in viable cells).
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